{"slug":"tb-500-skin","verification":{"valid":true,"entries":2,"head":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"},"energy":{"passes":2,"tokens_in":14430,"tokens_out":3002,"tokens_total":17432,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"},"provenance":[{"ts":"2026-06-29T23:31:08.585Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Skin\nSlug: tb-500-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Sin","response":"{\n  \"slug\": \"tb-500-skin\",\n  \"title\": \"TB-500 for Skin: Evidence-Graded Look at Repair Pathways\",\n  \"body\": \"## What's breaking down\\n\\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\\n\\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\\n\\n## Why TB-500 might help you\\n\\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\\n\\n## How these fit together\\n\\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\\n\\n## What the evidence actually shows\\n\\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in","tokens_in":14430,"tokens_out":3002,"cost":0,"prev":"genesis","hash":"a88682b21514d9f94e5f0a508512923ab68e940fdaaeaf38380bc83b2f7c1cd2"},{"ts":"2026-07-17T02:42:18.797Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-skin","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a88682b21514d9f94e5f0a508512923ab68e940fdaaeaf38380bc83b2f7c1cd2","hash":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"}]}